March 27, 2017
MDxHealth’s biomarkers for Prostate Cancer test could be used for the aggressive version of the disease
MDxHealth has reported results from a castration resistant prostate cancer (CRPC) treatment study.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
March 27, 2017
Erytech Pharma reports positive results from pancreatic cancer study
Erytech Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, has reported positive topline results from its Phase 2b clinical study evaluating its product candidate, eryaspase (GRASPA), in combination with chemotherapy for the treatment of second-line metastatic pancreatic cancer.
March 24, 2017
Novartis, PureTech Health team up for the potential treatment of conditions such as immunosenescence
PureTech Health said on Friday that it will advance with Novartis two clinical-stage programmes targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway.
March 23, 2017
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency
Three of Europe’s top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi <SASY.PA> and Roche <ROG.S> likely to win approvals for two new products, while GlaxoSmithKline <GSK.L> braces for a potential generic rival.
March 23, 2017
Teva Pharm may fire 6,000 workers – Israeli media report
Teva Pharmaceutical Industries <TEVA.TA> may fire as many as 6,000 workers worldwide as part of a multi-year efficiency plan, Israel’s Calcalist news website reported on Thursday.
March 23, 2017
Futura medical decreases loss in 2016
Futura medical, healthcare company focused on advanced transdermal technology, has announced its preliminary results for the year 2016.
March 23, 2017
£200 million to U.K. Biobank for genetics-guided drug development
A major research has been initiated, which will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.
March 23, 2017
Alcon wins FDA’s approval for its intraocular lens for cataract surgery patients
Alcon, a division of Novartis, has received approval from the US Food and Drug Administration (FDA) for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens (IOL) with Activefocus optical design for patients undergoing cataract surgery who choose to address their astigmatism and presbyopia at the same time.
March 22, 2017
Verona Pharma and QuintilesIMS in strategic agreement to develop respiratory drugs
Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, has entered into a global strategic services agreement with QuintilesIMS, a provider of biopharmaceutical development and commercial outsourcing services.
March 22, 2017
Galapagos nets $7.5 million from partner for reaching milestone in a study
Galapagos NV has reached a milestone in a Phase 1 study for cystic fibrosis, it is conducting with its partner AbbVie, …